ArticleJournal of chemical information and modeling2025
Machine Learning Approach for Predicting Drug-Like Molecules Targeting Calmodulin Pathway Proteins.
Article in Journal of chemical information and modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, numerous models have been developed to predict drug interactions with molecules. However, integrating diverse data sources and improving the accuracy of biological activity predictions remains a challenge. This work proposes a novel solution that addresses these limitations. Here, we have developed a machine learning model to predict the efficacy of different assays and drugs for diseases related to calmodulin. To achieve this, we have compiled a comprehensive data set including commercialized drugs and experimental compounds targeting CaM complexes. The IFPTML-XGB model achieved high predictive performance, with a test accuracy of 89.1% and a sensitivity of 89.0%, demonstrating its robustness for assay efficacy prediction. We have used the IFPTML modeling technique to identify key factors influencing these activities. We have also synthesized novel riluzole derivatives and have tested them both experimentally and computationally. Biological assays and molecular docking studies have been performed to provide a molecular-scale picture of the molecule-CaM interaction. To validate the model's utility, we tested it on these derivatives. We have found that the model correctly predicts which derivatives were the most bioactive, indicating that this framework can be used to identify promising candidates for new drug formulations. This research not only improves our understanding of CaM-related diseases, but also provides an effective framework for developing new treatments based on predictive modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.